粪便菌群移植在癌症治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.01

Abstract

Abstract: A large number of studies have proved that there is a close relationship between the imbalance of intestinal flora and human cancer.The intestinal flora not only plays a role in maintaining the intestinal barrier and metabolic nutrition,but more importantly,these microorganisms help to regulate local and systemic immune functions,and then participate in the pathogenesis of cancer.Fecal microbiota transplantation(FMT)is a method regulating the intestinal flora.Its effective mechanism is mainly based on the enhancement of beneficial microorganisms,the increase of microbial diversity and the recovery of normal flora.Recent studies have shown that microbial changes characterized by a significant increase in the number of pathogens and a relative decrease in the level of beneficial bacteria are related to the development of gastrointestinal and extra-gastrointestinal cancers,indicating that regulating intestinal flora is one of promising methods for the treatment of human cancer.This article focuses on the role of FMT in the treatment of digestive system cancer,non digestive system cancer and cancer related complications,and summarizes the latest progress of FMT in cancer treatment.

Key words: Intestinal flora, Fecal microbiota transplantation, Cancer

CLC Number:

WANG Hengmin, ZHAO Qi, WU Huaxing. Research progress of fecal microbiota transplantation in cancer treatment[J]. Journal of Practical Oncology, 2021, 35(5): 468-471.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.01

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/468

References

1 Zhang X,Zhao S,Song X,et al.Inhibition effect of glycyrrhiza polysaccharide(GCP)on tumor growth through regulation of the gut microbiota composition[J].J Pharmacol Sci,2018,137(4):324-332.
2 Hwang S,Lee CG,Jo M,et al.Enterotoxigenic bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model[J].Int J Med Sci,2020,17(2):145-152.
3 Eslami M,Yousefi B,Kokhaei P,et al.Importance of probiotics in the prevention and treatment of colorectal cancer[J].J Cell Physiol,2019,234(10):17127-17143.
4 Bashir A,Miskeen AY,Bhat A,et al.Fusobacterium nucleatum:an emerging bug in colorectal tumorigenesis[J].Eur J Cancer Prev,2015,24(5):373-385.
5 Lam SY,Yu J,Wong SH,et al.The gastrointestinal microbiota and its role in oncogenesis[J].Best Pract Res Clin Gastroenterol,2017,31(6):607-618.
6 Battipaglia G,Malard F,Rubio MT,et al.Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria[J].Haematologica,2019,104(8):1682-1688.
7 Geller LT,Barzily-Rokni M,Danino T,et al.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science,2017,357(6356):1156-1160.
8 Jacouton E,Chain F,Sokol H,et al.Probiotic strain lactobacillus casei BL23 prevents colitis-associated colorectal cancer[J].Front Immunol,2017,8:1553.
9 Zhang F,Cui B,He X,et al.Microbiota transplantation:concept,methodology and strategy for its modernization[J].Protein Cell,2018,9(5):462-473.
10 Santoni M,Piva F,Conti A,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Eur Urol,2018,74(4):521-522.
11 Filip M,Tzaneva V,Dumitrascu DL.Fecal transplantation:digestive and extradigestive clinical applications[J].Clujul Med,2018,91(3):259-265.
12 Ma C,Han M,Heinrich B,et al.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J].Science,2018,360(6391):5931.
13 Zhou D,Pan Q,Shen F,et al.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J].Sci Rep,2017,7(1):1529.
14 Ferrere G,Wrzosek L,Cailleux F,et al.Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J].J Hepatol,2017,66(4):806-815.
15 Chauhan A,Kumar R,Sharma S,et al.Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients:a pilot study[J].Dig Dis Sci,2021,66(3):873-880.
16 Mitsuhashi K,Nosho K,Sukawa Y,et al.Association of fusobacterium species in pancreatic cancer tissues with molecular features and prognosis[J].Oncotarget,2015,6(9):7209-7220.
17 Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science,2018,359(6371):97-103.
18 Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350(6264):1084-1089.
19 Chen D,Wu J,Jin D,et al.Fecal microbiota transplantation in cancer management:current status and perspectives[J].Int J Cancer,2019,145(8):2021-2031.
20 Parida S,Sharma D.The microbiome-estrogen connection and breast cancer risk[J].Cells,2019,8(12):1642.
21 Zhu J,Liao M,Yao Z,et al.Breast cancer in postmenopausal women is associated with an altered gut metagenome[J].Microbiome,2018,6(1):136.
22 Mullard A.Oncologists tap the microbiome in bid to improve immunotherapy outcomes[J].Nat Rev Drug Discov,2018,17(3):153-155.
23 Surawicz CM,Brandt LJ,Binion DG,et al.Guidelines for diagnosis,treatment,and prevention of clostridium difficile infections[J].Am J Gastroenterol,2013,108(4):478-498.
24 Konturek PC,Haziri D,Brzozowski T,et al.Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases[J].J Physiol Pharmacol,2015,66(4):483-491.
25 Gerassy-Vainberg S,Blatt A,Danin-Poleg Y,et al.Radiation induces proinflammatory dysbiosis:transmission of inflammatory susceptibility by host cytokine induction[J].Gut,2018,67(1):97-107.
26 Ding X,Li Q,Li P,et al.Fecal microbiota transplantation:a promising treatment for radiation enteritis?[J].Radiother Oncol,2020,143:12-18.
27 Nie X,Li L,Yi M,et al.The intestinal microbiota plays as a protective regulator against radiation pneumonitis[J].Radiat Res,2020,194(1):52-60.
28 Staffas A,Burgos da Silva M,van den Brink MR.The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease[J].Blood,2017,129(8):927-933.
29 Taur Y,Jenq RR,Perales MA,et al.The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation[J].Blood,2014,124(7):1174-1182.
30 Amrousy DE,El-Afify D,Shabana A.Relationship between bone turnover markers and oxidative stress in children with type 1 diabetes mellitus[J].Pediatr Res,2021,89(4):878-881.
31 Bakken JS,Polgreen PM,Beekmann SE,et al.Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection(RCDI)among infectious disease physicians[J].Anaerobe,2013,24:20-24.
32 Cammarota G,Ianiro G,Kelly CR,et al.International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J].Gut,2019,68(12):2111-2121.
33 Ridaura VK,Faith JJ,Rey FE,et al.Gut microbiota from twins discordant for obesity modulate metabolism in mice[J].Science,2013,341(6150):1241214.
34 Li SS,Zhu A,Benes V,et al.Durable coexistence of donor and recipient strains after fecal microbiota transplantation[J].Science,2016,352(6285):586-589.
35 Jalanka J,Mattila E,Jouhten H,et al.Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection[J].BMC Med,2016,14(1):155.
36 Le P,Nghiem VT,Mullen PD,et al.Cost-effectiveness of competing treatment strategies for clostridium difficile infection:a systematic review[J].Infect Control Hosp Epidemiol,2018,39(4):412-424.
37 Wang S,Xu M,Wang W,et al.Systematic review:adverse events of fecal microbiota transplantation[J].PLoS One,2016,11(8):e0161174.

[1]	ZHOU Tianhong, GU Xiuying, YAO Fang, SONG Shuming. Analysis for screening results of breast cancer in Urumqi from 2014 to 2018 [J]. Journal of Practical Oncology, 2021, 35(5): 391-395.
[2]	FU Yan¹, YAN Lili², WANG Chunyu², FU Fangmin², DONG Hua³. Analysis for the prevalence of malignant tumors in Qionghai city from 2010 to 2016 [J]. Journal of Practical Oncology, 2021, 35(5): 396-401.
[3]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[4]	HAN Shuling, YAO Yang, LIU Chao, ZHANG Yanqiao. Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(5): 476-479.
[5]	WU Changshuai, ZHANG Baohui, GAO Zhenglian, ZHANG Xiaowang, WANG Kun. Research progress in anti-tumor effect of propofol and its molecular mechanism in lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 480-484.
[6]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[7]	QIN Chao, LI Jiang, ZHENG Yadi, WANG Fei, CAO Wei, XU Yongjie, YU Yiwen, ZHAO Liang, YU Xinyang, CHEN Hongda, REN Jiansong, WANG Yong, LI Jing, LI Ni, CHEN Wanqing. Analysis of screening compliance and related factors in high-risk populations of breast cancer in Chinese cities [J]. Journal of Practical Oncology, 2021, 35(4): 291-296.
[8]	TUO Jiyu, ZHANG Xia, HE Xiaomei, JIANG Wenzhen, FENG Jueping, JIN Xia, ZHANG Min, WEI Shaozhong. Analysis of the screening results of the urban cancer early diagnosis and treatment project in Hubei province from 2018 to 2019 [J]. Journal of Practical Oncology, 2021, 35(4): 297-301.
[9]	LI Qingyu, YANG Lei, ZHANG Xi, LIU Shuo, LI Huichao, ZHANG Qian, CHENG Yangyang, JI Jiafu, WANG Ning. Discussion on the management of early diagnosis and treatment for cancer under the coronavirus disease(COVID-19) [J]. Journal of Practical Oncology, 2021, 35(4): 302-306.
[10]	GUO Lanwei, ZHANG Shaokai, LIU Shuzheng, ZHENG Liyang, CHEN Qiong, CAO Xiaoqin, SUN Xibin, ZHANG Jiangong. Analysis of compliance with breast cancer screening and its influencing factors in urban areas of Henan province [J]. Journal of Practical Oncology, 2021, 35(4): 307-313.
[11]	LIU Yanyu, LI Daojuan, LIANG Di, SHI Jin, JIN Jing, SHAN Baoen, HE Yutong. An analysis of the incidence and mortality of esophageal cancer in Hebei cancer registration area from 2011 to 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 314-320.
[12]	WANG Qin, LIN Ling, CAI Bo, TAO Changyu, WU Ming, HAN Renqiang, LUO Pengfei, YU Hao, MIAO Weigang, ZHOU Jinyi. Epidemic status of brain and nervous system tumors in Jiangsu province in 2015 and trend analysis from 2006 to 2015 [J]. Journal of Practical Oncology, 2021, 35(4): 321-326.
[13]	WU Jing, CUI Wangfei, CAO Ling, GUO Xuerong, MA Zhaohui, WANG Xinchen, ZHANG Ruifeng, ZHANG Yongzhen. Analysis for the incidence and death of upper gastrointestinal cancer in the cancer registration areas of Shanxi province in 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 327-331.
[14]	REN Siying, CHEN Yang, SHI Qingping, ZHU Yunfang, WEN Hongmei. Characteristics of lung cancer incidence and mortality from 2011 to 2016 in the cancer registration areas of Yunnan province and its time trend [J]. Journal of Practical Oncology, 2021, 35(4): 332-338.
[15]	MU Huijuan, LI Haina, LV Yi, SUN Lihua, WANG Lijuan, LI Yanxia, YU Fei, PAN Guowei, LIU Li. Analysis for 10-year survival rate of gastric cancer and its influencing factors among residents in three cities of Liaoning province [J]. Journal of Practical Oncology, 2021, 35(4): 339-343.

Research progress of fecal microbiota transplantation in cancer treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments